美國

證券交易委員會

華盛頓特區20549

表格 8-K

目前報告

根據1934年證券交易法第13條或第15(d)條的規定

報告日期（最早報告事件的日期）：2024年9月27日

AIMFINITY INVESTMENt CORP. I

（依憑章程所載的完整登記名稱）

華爾街9號西221號, PMb 235
威明頓, 特拉華州 19801

(總部辦公地址)

(425) 365-2933

(註冊人的電話號碼，包括區號）

(如有更改，請提供前名稱或前地址)

如果8-K表單的申報意圖同時滿足登記人在以下任何條款下的申報義務，請勾選下面適當的框。

根據美國《證券交易法》第12(b)條註冊的證券。

請在核取方塊內打勾，標明登記人是否符合《1933年證券法》第405條（本章節第230.405條）或《1934年證券交易法》第1202條（本章節第240.12條）中對新興成長型企業的定義。

新興成長公司☒

如果是成長中的企業，請打勾表示登記申請者選擇不使用延長過渡期來符合根據《交易法》第13(a)條提供的任何新的或修訂的財務會計標準。☐

項目2.03 建立 登記者直接財務負擔或不計入資產負債表安排的負債

二零二四年四月二十三日，艾姆菲尼特 投資公司 I，開曼群島豁免公司（」公司」)，召開股東特別大會（」股東 會議」)，如本公司股東批准修改本公司修訂及重訂的備忘錄及細則 協會的（」憲章」) 允許本公司直至 2024 年 4 月 28 日完成首次業務合併 並可選擇延長期限以完成初始業務合併最多九次，每次額外加一個月 （每個，a」每月延長」)，由於二零二五年一月二十八日止，最長可達九個月，以存款至本公司 信託帳戶（」信託帳戶」) 最低的是 (i) 所有公開股的 60 萬元及 (ii) 每股公開股份為 0.035 元 每次延長一個月的分享。

在2024年9月27日，公司向Aimfinity Investment LLC的成員及經理I-Fa Chang（以下簡稱為「認股權證」）發行了一份60,000美元的無抵押本票，作為公司（以下簡稱為「贊助商」）的贊助人設計師，以證明向公眾股東的trust賬戶支付的60,000美元（以下簡稱為「新月度展延付款」），可使公司將其首次業務組合的完成期限延長一個月，從2024年9月28日延長至2024年10月28日（以下簡稱為「新展延期）。新擴展是根據修改後章程允許的最多九個月度延期中的第六個。

該筆筆記不生息，並應全額支付，最早發生以下情形的日期：(i)公司業務組合完成；(ii)公司期限屆滿日期。以下情況構成違約事件：(i)未在到期日後五個業務日內支付本金；(ii)自願或非自願申請破產程序；(iii)公司未能履行其義務的違反；(iv)任何交叉違約；(v)對公司提出執行程序；及(vi)與履行其義務相關之任何不法和無效行為，此時可能加速該筆筆記。業務合併公司業務組合完成之日或公司期限屆滿之日。到期日筆記的到期日起計五個業務日內未支付本金；自願或非自願開始破產程序；公司未能履行其義務的違反；任何交叉違約；對公司提出執行程序；以及與履行其義務相關之任何不法和無效行為。

票據的收款人張先生有權利，但沒有義務，視情況全部或部分地將本票轉換為公司的定向增發單位（“定向增發單位”），該定向增發單位與公司同時完成的定向增發相同，惟需符合公司最終招股書（文件編號：333-263874）中描述的某些例外，並需在業務合併結束日至少兩個工作日前向公司提供書面通知轉換意向。與此轉換相關的贊助者所需收到的定向增發單位數量將由（x）贊助者應支付的未清償本金金額之和除以（y）10.00美元來確定。私募单位公司票據的付款人張先生有權利，但沒有義務，視情況全部或部分地將本票轉換為公司的定向增發單位（“”），該定向增發單位與公司同時完成的定向增發相同，惟需符合公司最終招股書（文件編號：333-263874）中描述的某些例外，並需在業務合併結束日至少兩個工作日前向公司提供書面通知轉換意向。與此轉換相關的贊助者所需收到的定向增發單位數量將由（x）贊助者應支付的未清償本金金額之和除以（y）10.00美元來確定。

該票據的發行是根據1933年證券法第4(a)(2)條所規定的豁免註冊進行的，該條款已根據修訂進行修正。

附有註釋副本的附件10.1是這份第8-k表格的當前報告，並並入參考。本2.03條款中所披露的內容僅屬摘要，須完全參照註釋。

項目3.02 非註冊出售股票。

本現行報告表格8-K條款2.03下披露的資訊將根據需要納入本條款3.02。 依據備註轉換而發行的私人份額（和底層證券），如果有的話，（1）在公司的首次業務組合完成之前，贊助人可能無法（在某些有限的例外情況下）轉讓或出售，（2）有權享有登記權。

項目 7.01 相關法規 FD 披露。

2024年9月27日，公司發布新聞稿（“公司新聞稿”），宣佈了新的延期計畫。本文件的附件99.1為公司新聞稿的副本。本文件第7.01項目和附件99.1不得視為《1934年證券交易所法》（“交易所法”）第18條修訂案的“申報”或在任何根據《1933年證券法》或《1934年證券交易所法》修訂案提交的文件中被引述。新聞稿公司宣布新延期。公司新聞稿的副本作為本展示99.1。本項目7.01中的信息和附件99.1不得視為1934年證券交易所法修訂案第18條的“申報”，也不得視為任何根據1933年證券法或修訂過的1934年證交法提報的文件中被引用，除非在該提交文件中以具體引用方式明確設定。證券交易所法案本文乃一2024年9月27日延期之公司新聞消息。公司新聞稿之附件99.1已附上。本文第7.01項及附件99.1所載資訊，不應視為已根據修訂自1934年《證券交易法》（“《交易所法》”）第18條之目的申報，或受該條款責任，亦不應視為被引用於根據1933年證券法或修訂後之1934年《證券交易法》，除非明確在該申報文件中以具體引用方式註明。

IMPORTANT NOTICES

Important Notice Regarding Forward-Looking Statements

As disclosed previously on the Current Report on Form 8-K filed on October 16, 2023, on October 13, 2023, AIMA entered into that certain Agreement and Plan of Merger (as may be amended, supplemented or otherwise modified from time to time, the “Merger Agreement”), with Docter Inc., a Delaware corporation (“Docter”), Aimfinity Investment Merger Sub I, a Cayman Islands exempted company and wholly-owned subsidiary of AIMA (“Purchaser”), and Aimfinity Investment Merger Sub II, Inc., a Delaware corporation and wholly-owned subsidiary of Purchaser (“Merger Sub”), pursuant to AIMA will enter into a business combination with Docter that involves a reincorporation merger and an acquisition merger.

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, both as amended. Statements that are not historical facts, including statements about the pending transactions described above, and the parties’ perspectives and expectations, are forward-looking statements. Such statements include, but are not limited to, statements regarding the proposed transaction, including the anticipated initial enterprise value and post-closing equity value, the benefits of the proposed transaction, integration plans, expected synergies and revenue opportunities, anticipated future financial and operating performance and results, including estimates for growth, the expected management and governance of the combined company, and the expected timing of the transactions. The words “expect,” “believe,” “estimate,” “intend,” “plan” and similar expressions indicate forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to various risks and uncertainties, assumptions (including assumptions about general economic, market, industry and operational factors), known or unknown, which could cause the actual results to vary materially from those indicated or anticipated.

Such risks and uncertainties include, but are not limited to: (i) risks related to the expected timing and likelihood of completion of the pending business combination, including the risk that the transaction may not close due to one or more closing conditions to the transaction not being satisfied or waived, such as regulatory approvals not being obtained, on a timely basis or otherwise, or that a governmental entity prohibited, delayed or refused to grant approval for the consummation of the transaction or required certain conditions, limitations or restrictions in connection with such approvals; (ii) risks related to the ability of AIMA and Docter to successfully integrate the businesses; (iii) the occurrence of any event, change or other circumstances that could give rise to the termination of the applicable transaction agreements; (iv) the risk that there may be a material adverse change with respect to the financial position, performance, operations or prospects of Docter or AIMA; (v) risks related to disruption of management time from ongoing business operations due to the proposed transaction; (vi) the risk that any announcements relating to the proposed transaction could have adverse effects on the market price of AIMA’s securities; (vii) the risk that the proposed transaction and its announcement could have an adverse effect on the ability of Docter to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers and on their operating results and businesses generally; (viii): risks relating to the medical device industry, including but not limited to governmental regulatory and enforcement changes, market competitions, competitive product and pricing activity; and (ix) risks relating to the combined company’s ability to enhance its products and services, execute its business strategy, expand its customer base and maintain stable relationship with its business partners. A further list and description of risks and uncertainties can be found in the prospectus filed on April 26, 2022 relating to AIMA’s initial public offering (the “IPO Prospectus”), the annual report of AIMA on Form 10-K for the fiscal year ended on December 31, 2022, filed on April 17, 2023 (the “Annual Report”), and in the registration statement on Form S-4 or Form F-4/proxy statement that will be filed with the SEC by Purchaser in connection with the proposed transactions, and other documents that the parties may file or furnish with the SEC, which you are encouraged to read. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. Accordingly, you are cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements relate only to the date they were made, and AIMA, Docter and their subsidiaries undertake no obligation to update forward-looking statements to reflect events or circumstances after the date they were made except as required by law or applicable regulation.

Additional Information and Where to Find It

In connection with the transaction described herein, Purchaser will file relevant materials with the SEC including the registration statement on Form S-4 or Form F-4 and a proxy statement (the “Registration Statement”). The proxy statement and a proxy card will be mailed to shareholders as of a record date to be established for voting at the stockholders’ meeting of Parent shareholders relating to the proposed transactions. Shareholders will also be able to obtain a copy of the Registration Statement and proxy statement without charge from Parent. The Registration Statement and proxy statement, once available, may also be obtained without charge at the SEC’s website at www.sec.gov. INVESTORS AND SECURITY HOLDERS OF PARENT ARE URGED TO READ THESE MATERIALS (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS IN CONNECTION WITH THE TRANSACTIONS THAT PARENT WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT PARENT, THE COMPANY AND THE TRANSACTIONS DESCRIBED HEREIN.

Participants in Solicitation

AIMA, Docter, and their respective directors, executive officers and employees and other persons may be deemed to be participants in the solicitation of proxies from the holders of AIMA’s ordinary shares stock in respect of the proposed transaction. Information about AIMA’s directors and executive officers and their ownership of AIMA ordinary shares is set forth in the IPO Prospectus and the Annual Report. Other information regarding the interests of the participants in the proxy solicitation will be included in the proxy statement pertaining to the proposed transaction when it becomes available. These documents can be obtained free of charge from the sources indicated above.

No Offer or Solicitation

This Current Report on Form 8-K is not a proxy statement or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the transactions described above and shall not constitute an offer to sell or a solicitation of an offer to buy the securities of AIMA or Docter, nor shall there be any sale of any such securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended, or an exemption therefrom.

Item 9.01 Financial Statements and Exhibits.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

4